Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs

Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.

    Tirthankar Chakraborty headshot

    5 Stocks to Buy for Remarkable Earnings Growth in 2017

    Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price

      The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group

      The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group

        Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

        Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

          Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

          Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

            Theravance Stock Up on Fast Track Status for Velusetrag

            Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.

              Swarup Gupta headshot

              5 Best Small-Cap Stocks for 2017

              Investing in small cap stocks with superior fundamentals will make for a profitable choice even in 2017.

                Bristol-Myers Reports Data from Opdivo Combination Studies

                Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

                  GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

                  GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

                    Acceleron, Celgene Present Myelodysplastic Syndromes Data

                    Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

                      Alexion Presents Data from Ultra-Rare Blood Disorder Study

                      Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.

                        Heat Biologics Stock Falls on Negative Bladder Cancer Data

                        Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

                          Cytori Scleroderma Study Two-Year Follow-Up Data Published

                          Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.

                            PhaseRx Soars on Orphan Drug Status for Rare Liver Disease

                            PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.

                              Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals

                              Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals

                                Kevin Matras headshot

                                This Value Screen Is Our Top Performer This Year

                                See how this screen has blown past the market and how you can start using it in your own portfolio. Highlighted stocks include CIM, PFSI and SCMP.

                                  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real Estate Equities

                                  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real Estate Equities

                                    Zacks.com featured highlights: Lancaster Colony, Foot Locker, ULTA Salon, Cosmetics & Fragrance, Sucampo Pharmaceuticals and Fox Factory Holding

                                    Zacks.com featured highlights: Lancaster Colony, Foot Locker, ULTA Salon, Cosmetics & Fragrance, Sucampo Pharmaceuticals and Fox Factory Holding